Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure - Full Text View

Sponsor:	Hillel Yaffe Medical Center
Information provided by:	Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:	NCT00834145

Purpose

Mobilization of fluid from the legs with the Normatec pump in patients with right heart failure, may empty the "reservoir" in the legs from excessive fluid, enabling fluid overload to collect there rather than in the liver or in other third spaces. Thus, we hypothesize that patients will lose weight, feel better, look better, be less prone to infections in their legs and to congestion of the liver.

Condition	Intervention
Right Heart Failure Cor Pulmonale	Device: A mechanical compression pump

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure: Short- Intermediate- and Long-Term Outcomes

Resource links provided by NLM:

MedlinePlus related topics: Edema Heart Failure

U.S. FDA Resources

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:

Patient weight [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Leg circumference, Pulmonary pressures, Cardiac function [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment:	30
Study Start Date:	March 2009
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.	Device: A mechanical compression pump Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc. Other Name: NormaTec Pump
No Intervention: 2 Routine medical treatment

Detailed Description:

The protocol will be divided into 2 parts:

The initial pumping phase will be an in-hospital study, short term study. Patients will be randomly assigned to conventional/conservative treatment or to pump therapy. Within 24 hours of admission patients assigned to pump therapy will be recruited for the study and will begin therapy according to the protocol outlined in the table below. These patients will not be given diuretics unless required to because of shortness of breath with suspected left heart failure. Individualized programs regarding pumping frequency and pump parameters will be set for each patient and will be adjusted during the first few days and maintained throughout the study unless there is a reason to modify them.

Data on both the conventional/conservative and the pump arms of the study will be collected at similar intervals. The duration of the in-hospital period will not be extended because of the study and is expected to be 3-7 days.
An intermediate-term study in which the patients from the phase 1 study will be ambulatory. During this phase of the study the effect of continuous maintenance and optimization will be monitored. Patients will come to the hospital for their pumping session at which time the protocol tests will be performed. Patients that were assigned to the conventional/conservative arm in phase 1 will be examined as per protocol at 1, 2 and 3 weeks after admission but BNP levels will be repeated only after the 3rd week.
At 3 and 6 months after admission, the "long term" phase of the study, a systematic investigation regarding repeat hospitalizations and their causes will be carried out by telephone interview and by a review of admission data from hospital records.

Eligibility

Ages Eligible for Study:	30 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hospitalized patients
Adults
Right heart failure secondary to pulmonary hypertension (cor pulmonale)
Pronounced leg edema

Exclusion Criteria:

Patients in sepsis
Hemodynamically unstable
Renal failure (creatinine >2 mg%)
Deep vein thrombosis
Pregnancy
Psychiatric/noncompliant patients
Patients who will not sign the informed consent form

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00834145

Contacts

Contact: David S. Blondheim, MD

972-46304488

blond@netvision.net.il

Locations

Israel
Hille Yaffe Medical Ceter	Not yet recruiting
Hadera, Israel, 38100
Principal Investigator: David S. Blondheim, MD

Sponsors and Collaborators

Hillel Yaffe Medical Center

More Information

No publications provided

Responsible Party:	David Blondheim, M.D., Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:	NCT00834145 History of Changes
Other Study ID Numbers:	32/2008
Study First Received:	February 2, 2009
Last Updated:	February 2, 2009
Health Authority:	Israel: Ministry of Health

Keywords provided by Hillel Yaffe Medical Center:

Edema
Right heart failure
Cor pulmonale
Pump
Leg compression

Additional relevant MeSH terms:

Edema
Heart Failure
Pulmonary Heart Disease

Signs and Symptoms
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on February 09, 2012